EX-99.1
2
dex991.htm
PRESS RELEASE
Press Release
Exhibit 99.1
Contact:
Will Roberts
Director, Corporate Communications
Phone (610) 321-6288
VIROPHARMA
INCORPORATED COMPLETES ACQUISITION
OF U.S. VANCOCIN BRAND
EXTON, Pa., November 10, 2004 - ViroPharma Incorporated (Nasdaq: VPHM) announced today that it has completed its acquisition of all
rights in the U.S. to manufacture, market and sell Vancocin Pulvules
®
, the oral capsule formulation of Vancocin (vancomycin hydrochloride), as well as rights to certain related Vancocin products from Eli Lilly and Company (NYSE: LLY).
About ViroPharma Incorporated
ViroPharma Incorporated is committed to the development and commercialization of products
that address serious diseases treated by physician specialists and in hospital settings. As a result of the acquisition completed today, ViroPharma will commercialize Vancocin Pulvules, approved for oral administration for treatment of enterocolitis
caused by
S. aureus
(including methicillin-resistant strains) and antibiotic-associated pseudomembranous colitis caused by
C. difficile
. (For prescribing information, please download the package insert at
http://www.viropharma.com/Vancocin_PI.pdf). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma and its development and commercial
products, visit the company's website at www.viropharma.com.
###

EX - 99 . 1 2 dex991 . htm PRESS RELEASE Press Release Exhibit 99 . 1 Contact : Will Roberts Director , Corporate Communications Phone ( 610 ) 321 - 6288 VIROPHARMA INCORPORATED COMPLETES ACQUISITION OF U . S . VANCOCIN BRAND EXTON , Pa . , November 10 , 2004 - ViroPharma Incorporated ( Nasdaq : VPHM ) announced today that it has completed its acquisition of all rights in the U . S . to manufacture , market and sell Vancocin Pulvules ® , the oral capsule formulation of Vancocin ( vancomycin hydrochloride ) , as well as rights to certain related Vancocin products from Eli Lilly and Company ( NYSE : LLY ) . About ViroPharma Incorporated ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings . As a result of the acquisition completed today , ViroPharma will commercialize Vancocin Pulvules , approved for oral administration for treatment of enterocolitis caused by S . aureus ( including methicillin - resistant strains ) and antibiotic - associated pseudomembranous colitis caused by C . difficile . ( For prescribing information , please download the package insert at http://www.viropharma.com/Vancocin_PI.pdf ) . ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus ( CMV ) and hepatitis C ( HCV ) . For more information on ViroPharma and its development and commercial products , visit the company 's website at www.viropharma.com . # # #
O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY O O O O O O O B-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY I-Parties.ACQUIRED_COMPANY O O O O O O B-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O